Accelerate Diagnostics (AXDX) & BIOLASE (BIOL) Financial Survey

Accelerate Diagnostics (NASDAQ: AXDX) and BIOLASE (NASDAQ:BIOL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends and earnings.

Volatility & Risk

Accelerate Diagnostics has a beta of 2.18, suggesting that its share price is 118% more volatile than the S&P 500. Comparatively, BIOLASE has a beta of 2.31, suggesting that its share price is 131% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent recommendations for Accelerate Diagnostics and BIOLASE, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Accelerate Diagnostics 0 1 1 0 2.50
BIOLASE 0 0 1 0 3.00

Accelerate Diagnostics presently has a consensus price target of $33.00, indicating a potential upside of 20.66%. BIOLASE has a consensus price target of $2.50, indicating a potential upside of 400.00%. Given BIOLASE’s stronger consensus rating and higher probable upside, analysts plainly believe BIOLASE is more favorable than Accelerate Diagnostics.

Profitability

This table compares Accelerate Diagnostics and BIOLASE’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Accelerate Diagnostics -3,085.36% -60.99% -57.85%
BIOLASE -36.28% -74.51% -40.81%

Institutional and Insider Ownership

47.9% of Accelerate Diagnostics shares are held by institutional investors. Comparatively, 38.8% of BIOLASE shares are held by institutional investors. 50.0% of Accelerate Diagnostics shares are held by insiders. Comparatively, 7.1% of BIOLASE shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Accelerate Diagnostics and BIOLASE’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Accelerate Diagnostics $250,000.00 6,060.76 -$66.37 million ($1.20) -22.79
BIOLASE $51.81 million 0.73 -$15.37 million ($0.33) -1.52

BIOLASE has higher revenue and earnings than Accelerate Diagnostics. Accelerate Diagnostics is trading at a lower price-to-earnings ratio than BIOLASE, indicating that it is currently the more affordable of the two stocks.

Summary

BIOLASE beats Accelerate Diagnostics on 9 of the 13 factors compared between the two stocks.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.

BIOLASE Company Profile

BIOLASE, Inc. (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers. It offers two categories of laser system products: WaterLase (all-tissue) systems and Diode (soft tissue) systems. Its brand, WaterLase, uses a combination of water and laser energy to perform procedures performed using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. It also offers its Diode laser systems to perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. Its Waterlase and Diode systems use disposable laser tips of differing sizes and shapes depending on the procedures being performed.

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply